Tarsus Pharmaceuticals, Inc.

TARS·NasdaqGS·Healthcare
Compare
69.07−3.57 (−4.91%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close72.64
Open74.01
Day range65.3674.63
52-week range53.8991.53
Off day high−7.44%
Off 52-week high−24.54%
Volume2.55M
Avg. volume (3M)831.76K
Market cap3.23B
EPS (TTM)-15.86
Forward P/E-138.14
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding46.79M
Short interest11.96% of float
Earnings dateNov 3, 2026
Analyst target99.33
Profit margin−102.93%

Against its peers

Compare in full ›
TARS 4576.T 1477.HK OCUL PVLA YDES
Market cap 3.23B 3.11B 4.05B 1.57B 2.34B 492.28M
P/E (TTM) — — — — — —
Forward P/E -138.1 — 17.3 -4.8 -20.5 —
Price/book 32.7 2.2 1.0 3.0 10.8 110.3
Dividend yield — — — — — —
1-year change +6.51% −47.12% −40.60% −36.91% +101.89% −39.33%
Today −4.91% −1.82% +0.30% +4.69% +6.11% +7.84%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.

Related companies

Compare ›

The businesses closest to Tarsus Pharmaceuticals's by what they do, from their descriptions, with the same industry weighted in.

Company Mkt cap Price Today
D. Western Therapeutics Institute, Inc.4576.T · Biotechnology 3.11B 54.00 −1.82%
Ocumension Therapeutics1477.HK · Biotechnology 4.05B 5.070 +0.30%
Ocular Therapeutix, Inc.OCUL · Biotechnology 1.57B 7.14 +4.69%
Palvella Therapeutics, Inc.PVLA · Biotechnology 2.34B 162.28 +6.11%
YD Bio LtdYDES · Biotechnology 492.28M 6.95 +7.84%
Fortress Biotech, Inc.FBIO · Biotechnology 65.70M 1.9700 +1.55%
Clinuvel Pharmaceuticals LimitedCUVL · Biotechnology 247.39M 4.9000 −3.45%
Regeneron Pharmaceuticals, Inc.REGN · Biotechnology 96.28B 930.67 −4.39%

Also based in Irvine, California, then elsewhere in California.

Company Mkt cap Price Today
Skyworks Solutions, Inc.SWKS · Irvine, CAOdds 19.50B 82.92 −2.90%
Rivian Automotive, Inc.RIVN · Irvine, CAOdds 20.52B 14.06 +5.79%
Edwards Lifesciences CorporationEW · Irvine, CA 57.28B 99.37 +4.39%
American Healthcare REIT, Inc.AHR · Irvine, CA 12.29B 56.37 +2.62%
Ingram Micro Holding CorporationINGM · Irvine, CA 6.01B 26.12 −1.47%
Boot Barn Holdings, Inc.BOOT · Irvine, CA 4.35B 145.56 +8.96%
SpyGlass Pharma, Inc.SGP · Irvine, CA 1.15B 34.45 0.00%
Beta Bionics, Inc.BBNX · Irvine, CA 921.52M 16.95 +12.25%

What visitors to Tarsus Pharmaceuticals's page also look at.

Company Mkt cap Price Today
Phathom Pharmaceuticals, Inc.PHAT 461.74M 5.68 −1.05%
Edgewise Therapeutics, Inc.EWTX 4.08B 37.53 −0.40%
Stoke Therapeutics, Inc.STOK 1.78B 27.45 +1.70%
Praxis Precision Medicines, IncPRAXOdds 7.95B 284.79 +1.53%
4D Molecular Therapeutics, Inc.FDMT 678.40M 12.28 +2.76%

From the 4SEARCH.business instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 20 min.

Latest news

All TARS news ›
Orange County Business Journal·Negative

Tarsus Pharmaceuticals Shares Fall 5.3% on Wider Loss

Acquisitions drive $632M in R&D expenses Revenue rose 64% to $194.6 million during the quarter, exceeding the Zacks Consensus estimate by 3%. Despite revenue topping estimates, net loss widened to $668.3 million during the third quarter,…

TARSBCS
Seeking Alpha··3 outletsPositive

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST David Nakasone - Head of Investor RelationsBobak Azamian - Co-Founder, President, CEO & ChairmanNeera Clase - Chief Commercial OfficerJeffrey S. Farrow…

TARSABOSBAC
More from 2 other outlets
@VisionMonday·Positive

Tarsus Reports Q3 2026 Results, Raises Xdemvy Guidance | VM

IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) a biopharmaceutical company focused on the development and commercialization of therapeutic eyecare treatments, announced financial results for the third quarter ended September…

TARSVNDA
The Manila Times·Positive

Tarsus Reports Third Quarter 2026 Financial Results

Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch…

TARS
Seeking Alpha·Positive

My 'Eye' Is On Tarsus Pharmaceuticals

(NASDAQ:TARS) Seeking Alpha - Tarsus Pharmaceuticals is well-positioned with Xdemvy's rapid commercial ramp and robust $2B peak sales potential. - Recent acquisitions of IRX-101 and ALK-101 diversify the pipeline, adding both low-risk and…

LLYJNJMRKPFE
@VisionMonday·Positive

Tarsus Names Neera Clase Chief Commercial Officer | VM

IRVINE, Calif.—Tarsus Pharmaceuticals Inc. (Nasdaq: TARS), a biopharmaceutical company focused on therapeutic eyecare, has announced the appointment of Neera Clase as chief commercial officer (CCO), effective November 1, 2026. IRVINE,…

TARS

From the 4Search news index, newest first.

In the news

18mentions in 30 days
12with it in the headline
Positivesentiment

Mentioned with

Tarsus Pharmaceuticals, Inc.12Stargardt11U.S. Food and Drug Administration10Northstar8Barclays6Eli Lilly and Company5Johnson & Johnson5Astrazeneca4

People in the coverage

Danessa Lincoln14Michael Walen14Marketbeat13Alkeus9Kim Johansen9Mitch Edgeman6

Themes

Healthcare12SEC Filings7Earnings6Financial4Lly4Results4Comparison3Jnj3

Most coverage from

  1. seekingalpha.com4
  2. themarketsdaily.com3
  3. defenseworld.net2
  4. theglobeandmail.com2
  5. visionmonday.com2

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance